Markers of Infection and Resistance in Invasive Fusariosis

Last updated: February 22, 2024
Sponsor: Central Hospital, Nancy, France
Overall Status: Active - Recruiting

Phase

N/A

Condition

Systemic Fungal Infections

Treatment

biomarkers

Clinical Study ID

NCT04937751
2020PI202
  • All Genders

Study Summary

In recent decades, invasive fusarioses have been emerging fungal pathologies with high mortality. The prognosis depends on the speed of the diagnosis, but currently biological diagnosis is mainly based on fungal culture, no specific biomarker for this microorganism is available in current clinical practice. The genus Fusarium also shows reduced sensitivity to antifungals commonly used and recommended in clinical practice, such as voriconazole or amphotericin B.

The main objective of this study is to describe the proportions of different fungal species in positive fungal cultures in patients with invasive fungal infection (IFI) or fungal keratitis. The secondary objectives are the description of the dosage of galactomannans, beta (1,3) -D-glucans and the rate of detection of DNA circulating in case / control groups for the 2 clinical forms studied. In patients with evidence of Fusarium wilt, the study will describe the distribution of the different minimum inhibitory concentrations (MIC) depending on whether or not different antifungals are taken, the vital status at 3 months, and the response or not to treatment. Finally, the presence of genetic markers will be described according to the groups of MIC values.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Suspicion of invasive fungal infection involving the performance of a blood culture ora skin biopsy or diagnosis of keratitis involving the taking of a cornea sample
  • Fungal culture carried out on this sample
  • Person having been informed of the research and not having opposed the use of theirdata

Exclusion

Exclusion Criteria:

  • Clinical diagnosis of superficial fusarium wilt (onychomycosis, etc.)

Study Design

Total Participants: 150
Treatment Group(s): 1
Primary Treatment: biomarkers
Phase:
Study Start date:
July 19, 2023
Estimated Completion Date:
July 31, 2028

Connect with a study center

  • CHRU Nancy

    Vandoeuvre les nancy, 54500
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.